Objective: To establish whether children with relapsing acquired demyelinating syndromes (RDS) and myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) show distinctive clinical and radiologic features and to generate a diagnostic algorithm for the main RDS for clinical use.
Pediatric relapsing acquired demyelinating syndromes (RDS) 1 of the CNS define a group of diseases with different phenotypes. The most common pediatric RDS is multiple sclerosis (MS). The 2010 McDonald criteria enable a diagnosis of MS in children .11 years of age presenting with a clinically isolated syndrome (CIS) and MRI evidence of dissemination in space and time, 2 provided that the clinical presentation does not resemble acute disseminated encephalomyelitis (ADEM). 3, 4 Although a proportion of children present with MS before the age of 12 years, the 2010 McDonald criteria 2 show a low positive predictive value 5 in this patient group.
Another RDS is neuromyelitis optica spectrum disorder (NMOSD), which is stratified according to the presence/absence of aquaporin-4 (AQP4) antibodies (Ab). 6 About 30% of adult patients with AQP4-seronegative NMOSD have myelin oligodendrocyte glycoprotein (MOG) Ab. 7 Comparative studies between MOG-Ab-and AQP4-Ab-positive NMOSD in adults [8] [9] [10] and children 11 have shown that MOG-Ab-positive patients are younger, are more frequently male, and have a better outcome and more often a monophasic course.
In addition to AQP4-Ab-seronegative NMOSD, 12 MOG-Ab have been detected in other RDS such as multiphasic disseminated encephalomyelitis (MDEM), 13 relapsing optic neuritis (RON), 14 and ADEM followed by recurrent or monophasic optic neuritis (ON). 15 We evaluated retrospectively a large cohort of children with RDS who underwent clinical assessments, MRI, oligoclonal band (OCB) testing in the CSF, and AQP4-Ab, MOGAb, and Epstein-Barr virus (EBV) Ab testing in the serum as part of routine clinical protocols. We aimed to identify the key features of RDS that unify phenotypes and focused on patients with MOG-Ab to investigate whether they show distinct clinical and radiologic features that are independent of their original diagnosis. Our ultimate goal was to develop a diagnostic algorithm that provides advice on how to reach the diagnosis of the newly defined phenotypes by suggesting sequential diagnostic tests and supporting features. Standard protocol approvals, registrations, and patient consents. This study was approved by Great Ormond Street Hospital Research and Development Department (reference 16NC10).
Procedure. All clinical records were reviewed by the first author (Y.H.), who summarized patients' demographics, clinical presentations, demyelinating phenotypes at visits, timing and features at relapses, and Expanded Disability Status Scale at 2 years from onset. Onset demyelinating phenotype was determined on the basis of the clinical features and neurologic examination according to established criteria 3 (without neuroimaging reference) as being ON, transverse myelitis (TM), or neurologic deficits associated with encephalopathy (ADEM) or without encephalopathy (a brainstem, cerebellar, and hemispheric CIS).
All patients had undergone brain and spinal cord imaging according to local MRI protocols (not routinely including orbits). Gadolinium-enhanced imaging was performed in all cases but not always at the first scan.
Within 1 month of an acute event (either onset or relapse), clinically symptomatic children underwent testing for serum AQP4-Ab and MOG-Ab (not CSF) as part of routine assessments of children with demyelinating diseases at the Clinical Neuroimmunology service at the Oxford Radcliffe Hospital Trust using live cell-based assays. 16, 17 (This laboratory receives samples for Ab testing from all over the world, including the United States, where MOG-Ab testing is not available.) Qualitative analyses of serum and CSF oligoclonal patterns were performed by isoelectric focusing on agarose gels followed by immunoblotting, 18 performed a separate analysis to assess whether imaging characteristics alone can support the diagnosis of a specific syndrome while blinded to the clinical features and the Ab results. The following analysis was repeated separately for baseline MRI and follow-up scans. Lesion morphology, distribution, and location were used to support a diagnosis of MS. MS plaques are oval and oriented perpendicular to the ventricular surface. They occur bilaterally but are typically asymmetric, and they are distributed in both the supratentorial and infratentorial compartments. Although MS lesions can be located anywhere in the CNS, they are frequently seen in the juxtacortical, periventricular, and infratentorial regions. 19 MRI scans were grouped into the following categories; (1) not MS, (2) not typical of MS, (3) some MS features, or (4) typical of MS.
For categories 1 and 2, one of the following 5 main imaging patterns, which included features known to be associated with NMOSD 6, 20 and features recently reported in patients with MOG-Ab, 13, 21 was chosen by the neuroradiologist as the predominant pattern: (1) disease localized to brainstem and hypothalamus; (2) predominantly confluent, hazy/poorly marginated lesions involving both gray matter and white matter; (3) extensive confluent leukodystrophy-like MRI pattern; (4) sharply demarcated hemispheric white matter lesions (.3 cm); or (5) TM and/ or ON with normal intracranial appearance or nonspecific white matter lesions. In addition, for the follow-up scans, the 2 following imaging features were looked for: almost or complete resolution of lesions and destructive lesions, defined as severe rarefaction of tissue leading to central low signal on fluidattenuated inversion recovery with associated volume loss.
Finally, the presence of lesions in the diencephalon, dorsal brainstem, periependymal area surrounding the lateral ventricles, longitudinally extensive TM (LETM), cortical gray matter, thalamus, basal ganglia, juxtacortical and deep white mater involvement more than periventricular, cerebellar peduncles, pons, and optic nerves/tracts, considered to be typical of patients with NMOSD with AQP4-Ab-(according to Wingerchuk et al 6 criteria) 20 and MOG-Ab-associated demyelination, was recorded.
Statistical analysis. To compare the demographic, clinical, radiologic, and serologic characteristics between the phenotypes, parametric or nonparametric statistical tests (Mann-Whitney U and Kruskal-Wallis tests) were used for continuous distributions as appropriate given normality, and x 2 or Fisher exact tests were used for nominal data. Results associated with a value of p ,0.05 were considered significant. Data were analyzed with GraphPad Prism 5.
RESULTS One hundred ten consecutive children with RDS were studied. The median length of follow-up (from first clinical presentation) was 4 years (interquartile range 3-7 years). During this period, a median of 4 (range 3-10) repeated MRI scans were performed. All patients had brain MRI at onset, and 95 of 110 (86.3%) also had spinal cord MRI.
The figure e-2 ). All 45 patients with spinal cord lesions had short segment myelitis, in contrast to 12 of 13 patients in the non-MS group who had LETM (p , 0.0001). 
Destructive lesions at follow-up scans were seen in the majority of AQP4-Ab-positive patients (62.5%) and in none of the MOG-positive patients (p 5 0.002) (table 3 and figure e-4). Lesions located in dorsal brainstem were more frequently seen in AQP4-Ab-positive patients (87.5% vs 11.5%, p 5 0.0085), while lesions in the cerebellar peduncles were seen in only the MOG-positive patients at onset and follow-up (p 5 0.03 and p 5 0.011) (table 3 and figure 1 ). Finally, leukodystrophy-like lesions were seen only in MOG-Ab-positive patients (table 3 and figure 1 ).
Diagnostic algorithm. We propose a diagnostic algorithm (figure 2), applicable to any episode of CNS demyelination, that leads to 4 main demyelinating syndromes: MS, AQP4-Ab NMOSD, MOG-Abassociated disease, and Ab-negative RDS.
The first recommended diagnostic test is brain and spinal cord MRI. If the clinical features of a CNS attack and MRI findings are considered to be typical or suggestive of MS, then the McDonald diagnostic criteria should be applied.
In children whose MRI is not typical or suggestive of MS but who have clinical and radiologic features suggestive of NMOSD, AQP4-Ab testing is recommended, particularly in children having an area postrema syndrome, MRI abnormalities localized to the brainstem and hypothalamus, and destructive lesions. MOG-Ab should be tested in AQP4-Ab-negative cases.
In children whose MRI is not typical of MS or NMOSD but the clinical and radiologic presentation resembles ADEM, MOG-Ab testing is recommended. Additionally, MOG-Ab testing is recommended in children with poorly marginated lesions in the cerebellar peduncle and in children with a leukodystrophy-like MRI pattern.
Consideration of alternative diagnoses (e.g., inflammatory, infectious, and neurometabolic) and then monitoring are recommended in the remaining minority of Ab-negative RDS.
DISCUSSION On the basis of the observations in this large cohort of 110 children with RDS, a diagnostic algorithm applicable to any episode of CNS demyelination in children was developed to reach the diagnosis of 4 main phenotypes: MS, AQP4-Ab NMOSD, MOG-Ab-associated disease, and seronegative RDS children.
Brain and spinal cord MRI is the first diagnostic test to be performed. This helps to reach the diagnosis of MS, which is the most common RDS in our cohort (56.4%), even if the MRI is analyzed blindly in isolation. The lack of clinical, radiologic, and immunologic differences between children with MS ,11 and .11 years of age suggests that the 2010 McDonald diagnostic criteria for MS 2 can be applied to children of any age. Current guidance 3 for the diagnosis of MS in children recommends caution for children ,12 years of age, but our study indicates that if clinical and MRI features typical of adult MS are seen in children, there should be confidence in the diagnosis of MS.
None of the children with MS presented with ADEM. Previous studies have shown that 5% to 29% of children 23, 24 initially diagnosed with ADEM have further demyelinating events that are atypical for ADEM but lead to a diagnosis of MS. However, MOG-Ab were not tested in these patients. These previous studies have reported that children with MS showed unique MRI features such as edema and widespread white matter involvement, increased frequency of LETM, and lower frequencies of intrathecal OCB positivity than adults with MS, 1,23 while these features were absent in our patients with MS but typical of MOG-Ab-associated disease.
AQP4-Ab testing should be performed in patients with clinical and/or radiologic features suggestive of NMOSD. 6 We found that two-thirds of children without MS had NMOSD, of whom 30.7% tested were AQP4-Ab positive, which is lower than previously Table 2 Comparison of clinical and paraclinical features in all MOG-Ab-positive and AQP4-Ab-positive children Blinded radiologic analysis stratified to antibody positivity reported in adult 8, 21, 25 and pediatric cohorts. 26 This is in keeping with previous observations of AQP4-Ab seropositivity exponentially increasing with age, particularly in women. 27 Nevertheless, comparison between different cohorts has to be made with caution if referral pathways are different between centers.
We found that 82.9% of all patients with non-MS RDS were either AQP4-Ab or MOG-Ab positive. We detected MOG-Ab in 83.3% of NMOSD without AQP4-Ab. This was much higher than in previously reported adult cohorts 7 but not surprising because MOG-Ab are known to be common in children. 28 In addition, increasing recognition of this Ab and the application of the latest diagnostic criteria for NMOSD 6 may contribute to the observed high number of patients with NMOSD 29 and hence MOGAb-positive cases. CSF testing for AQP4-Ab and MOG-Ab was not performed because in both of these conditions it has been shown that the Ab originate from the periphery and serum testing is more sensitive than CSF.
30,31
Because we found that 100% of patients with MDEM are MOG-Ab-positive and previous investigations detected a significant association between ADEM and MOG-Ab, 13, 32 we feel that performing MOG-Ab testing in all patients presenting with ADEM (both monophasic and relapsing disease) is justified on the bases of expert opinion consensus. A key question is whether patients with MOG-Abnegative ADEM show different clinical and MRI features from patients with MOG-Ab-positive ADEM. Large, ill-defined lesions in the cerebellar peduncle and a leukodystrophy-like MRI pattern can be useful clues to this diagnosis.
Despite the low number of children with AQP4-Ab in this cohort, we identify differences between children with AQP4-Ab and children with MOGAb grouped together (independently of their original RDS diagnosis). Children with MOG-Ab were younger, less likely to present with area postrema syndrome, and more likely to present with ADEM; had lower disability at 2 years; and had a longer time to relapse than AQP4-Ab NMOSD. Therefore, we proposed grouping all the MOG-Ab-positive patients into a unified phenotype: MOG-Abassociated disease. It is possible that the 2 antigenic targets (AQP4 and MOG) lead to different diseases via different pathogenic mechanisms, which cause an autoimmune astrocytopathy in AQP4-Abassociated disease and autoimmune oligodendrogliopathy in MOG-Ab-associated disease. 33 Recent studies looking at the effects of MOG-Ab in cell cultures and in mouse models showed loss of the microtubule cytoskeleton of oligodendrocytes when incubated with purified IgG from MOG-Abpositive patients, 34 as well as myelin changes and altered expression of axonal proteins when injected directly into mouse brain. 35 In contrast, AQP4-Ab are thought to produce astrocyte damage by complement-dependent cytotoxicity, which leads to blood-brain barrier disruption, causing leukocyte infiltration, and cytokine release, resulting in damage to oligodendrocytes, myelin, and neurons, which may explain the more destructive lesions seen in this phenotype. 36 An abundance of AQP4 in the area postrema 37 is likely to explain the increased frequency of nausea and vomiting in the AQP4-Ab-positive group, together with imaging abnormalities in the dorsal brainstem and hypothalamus, as previously reported. 38 Overall, the very high percentage (82.9%) of children with non-MS RDS who are positive for 1 of the 2 Ab suggests that the majority of these children have a known Ab-mediated demyelinating disease. In the rare cases of RDS other than MS, negative to both Ab, it is important to consider mimics of CNS demyelination. The blinded MRI analyses successfully distinguished between MS and non-MS cases already at onset. MRI abnormalities in the brainstem and hypothalamus were typical of AQP4-Ab-positive patients, as previously reported, 38 while ill-defined lesions in the cerebellar peduncle were seen exclusively in the MOG-Ab-positive patients. Future studies will aim to confirm whether this can be used as a marker for MOG-Ab-associated disease.
Intrathecal OCBs and the remote EBV infection confirmed previous findings, 39 ,40 but because we did not calculate the predictive value of these tests and their role independently of MRI, we decided not to include them in the algorithm.
A limitation of our study is its retrospective nature, which led to the inclusion of only relapsing cases. However, this large cohort allowed us to identify notable differences in their clinical, imaging, and immunologic characteristics that have led us to propose 4 main distinct phenotypes: MS, NMOSD with AQP4-Ab, MOG-Ab-associated disease, and seronegative RDS. The distinction of MOG-Ab-associated disease from the other RDS should be considered in the next revisions of the diagnostic criteria for MS and NMOSD. 
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The first recommended diagnostic test is brain and spinal cord MRI. If MRI findings are considered to be typical or suggestive of adult MS, then the McDonald diagnostic criteria should be applied. In children whose MRI is not typical or suggestive of MS but who have clinical and radiologic features suggestive of NMOSD, AQP4-Ab testing is recommended. In particular, this test is advised in children presenting with an area postrema syndrome, MRI abnormalities localized to the brainstem and hypothalamus, and destructive lesions. If AQP4-Ab are negative, then MOG-Ab should be tested. In children whose MRI is not typical of MS or NMOSD but the clinical and radiologic presentation has features of ADEM, MOG-Ab testing is recommended. Supporting features for MOG-Ab-associated disease include lesions in the cerebellar peduncle and leukodystrophy-like MRI pattern in the very young. Alternative diagnoses should be considered in the remaining Ab-negative patients. Ab 5 antibodies; ADEM 5 acute disseminated encephalomyelitis; AQP4 5 aquaporin-4; MOG 5 myelin oligodendrocyte glycoprotein; MS 5 multiple sclerosis; NMOSD 5 neuromyelitis optica spectrum disorder.
